BACKGROUND: Contemporary treatment of node-positive (N+) colon cancer consists of adjuvant chemotherapy; however, randomized data supporting this practice were derived from lesions T2 or greater. Minimal data exist regarding the use and need for adjuvant chemotherapy in T1N+ disease. OBJECTIVE: The aim of this study was to determine treatment trends and the effects of adjuvant chemotherapy on T1N+ colon cancers by using the National Cancer Database. DESIGN: This was a retrospective study. Baseline demographics, tumor, and cancer treatment characteristics were compared. Groups were matched on the propensity to receive chemotherapy. Adjusted long-term survival stratified by chemotherapy use was compared by using the Kaplan-Meier method with the log-rank test. Predictors of not receiving chemotherapy were identified by using a multivariable logistic regression model. SETTINGS: Data were collected from the National Cancer Database, which collects cancer data from over 1500 cancer centers. PATIENTS: We identified patients from 1998 to 2006 with T1N+ disease, excluding those with metastatic disease or previous cancer. Patients were stratified based on whether or not they received chemotherapy. MAIN OUTCOME MEASURES: The primary outcome measure of this study was long-term survival. RESULTS: Three thousand one hundred thirty-seven patients had T1N+ disease; 70.6% (n = 2216) received chemotherapy, and utilization significantly increased from 1998 to 2011 (p < 0.001). Unadjusted analysis revealed that patients treated with chemotherapy were statistically younger and healthier, and had shorter postoperative lengths of stay (all p < 0.001). Unadjusted 5-year survival was higher in patients receiving chemotherapy (87.9% vs 63.0% in patients with no chemotherapy; p < 0.001) and this persisted after propensity matching with (83.4% and 63.0% in patients with or without chemotherapy; p < 0.001). Only age (OR, 0.29; p < 0.001) predicted not receiving chemotherapy. LIMITATIONS: Limitations include potential selection bias as well as the inability to compare disease-free survival/recurrence. CONCLUSIONS: Adjuvant chemotherapy appears to significantly improve long-term survival in patients receiving chemotherapy in T1N+ disease. Thus, the use of chemotherapy in T1N+ disease is justified and provides a highly significant survival benefit.
BACKGROUND: Contemporary treatment of node-positive (N+) colon cancer consists of adjuvant chemotherapy; however, randomized data supporting this practice were derived from lesions T2 or greater. Minimal data exist regarding the use and need for adjuvant chemotherapy in T1N+ disease. OBJECTIVE: The aim of this study was to determine treatment trends and the effects of adjuvant chemotherapy on T1N+ colon cancers by using the National Cancer Database. DESIGN: This was a retrospective study. Baseline demographics, tumor, and cancer treatment characteristics were compared. Groups were matched on the propensity to receive chemotherapy. Adjusted long-term survival stratified by chemotherapy use was compared by using the Kaplan-Meier method with the log-rank test. Predictors of not receiving chemotherapy were identified by using a multivariable logistic regression model. SETTINGS: Data were collected from the National Cancer Database, which collects cancer data from over 1500 cancer centers. PATIENTS: We identified patients from 1998 to 2006 with T1N+ disease, excluding those with metastatic disease or previous cancer. Patients were stratified based on whether or not they received chemotherapy. MAIN OUTCOME MEASURES: The primary outcome measure of this study was long-term survival. RESULTS: Three thousand one hundred thirty-seven patients had T1N+ disease; 70.6% (n = 2216) received chemotherapy, and utilization significantly increased from 1998 to 2011 (p < 0.001). Unadjusted analysis revealed that patients treated with chemotherapy were statistically younger and healthier, and had shorter postoperative lengths of stay (all p < 0.001). Unadjusted 5-year survival was higher in patients receiving chemotherapy (87.9% vs 63.0% in patients with no chemotherapy; p < 0.001) and this persisted after propensity matching with (83.4% and 63.0% in patients with or without chemotherapy; p < 0.001). Only age (OR, 0.29; p < 0.001) predicted not receiving chemotherapy. LIMITATIONS: Limitations include potential selection bias as well as the inability to compare disease-free survival/recurrence. CONCLUSIONS: Adjuvant chemotherapy appears to significantly improve long-term survival in patients receiving chemotherapy in T1N+ disease. Thus, the use of chemotherapy in T1N+ disease is justified and provides a highly significant survival benefit.
Authors: Al B Benson; J Pablo Arnoletti; Tanios Bekaii-Saab; Emily Chan; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Raza A Dilawari; Paul F Engstrom; Peter C Enzinger; James W Fleshman; Charles S Fuchs; Jean L Grem; James A Knol; Lucille A Leong; Edward Lin; Kilian Salerno May; Mary F Mulcahy; Kate Murphy; Eric Rohren; David P Ryan; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; William Small; Constantinos T Sofocleous; Alan P Venook; Christopher Willett Journal: J Natl Compr Canc Netw Date: 2011-11 Impact factor: 11.908
Authors: Scott R Steele; Grace E Park; Eric K Johnson; Matthew J Martin; Alexander Stojadinovic; J A Maykel; Marlin W Causey Journal: Dis Colon Rectum Date: 2014-03 Impact factor: 4.585
Authors: Satoshi Okabe; Jinru Shia; Garrett Nash; W Douglas Wong; José G Guillem; Martin R Weiser; Larissa Temple; Kenichi Sugihara; Philip B Paty Journal: J Gastrointest Surg Date: 2004-12 Impact factor: 3.452
Authors: Ryan P Merkow; David J Bentrem; Mary F Mulcahy; Jeanette W Chung; Daniel E Abbott; Thomas E Kmiecik; Andrew K Stewart; David P Winchester; Clifford Y Ko; Karl Y Bilimoria Journal: Ann Surg Date: 2013-12 Impact factor: 12.969
Authors: Barbara A Curbow; Amy B Dailey; Evelyn C King-Marshall; Tracy E Barnett; Jessica R Schumacher; Shahnaz Sultan; Thomas J George Journal: Am J Public Health Date: 2015-02-25 Impact factor: 9.308
Authors: Yara Backes; Sjoerd G Elias; Bibie S Bhoelan; John N Groen; Jeroen van Bergeijk; Tom C J Seerden; Hendrikus J M Pullens; Bernhard W M Spanier; Joost M J Geesing; Koen Kessels; Marjon Kerkhof; Peter D Siersema; Wouter H de Vos Tot Nederveen Cappel; Niels van Lelyveld; Frank H J Wolfhagen; Frank Ter Borg; G Johan A Offerhaus; Miangela M Lacle; Leon M G Moons Journal: BMC Med Date: 2017-07-14 Impact factor: 8.775